Ademi LLP is investigating Ocuphire (Nasdaq: OCUP) for possible breaches of fiduciary duty and other violations of law in its transaction with Opus Genetics.
In the transaction, Ocuphire will issue 5.2 million shares of its common stock and 14.1 thousand shares of its convertible preferred stock to existing stockholders of Opus Genetics. Ocuphire insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Ocuphire’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.